134 related articles for article (PubMed ID: 17352099)
1. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis.
Park IN; Hong SB; Oh YM; Lim CM; Lee SD; Lew WJ; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
Int J Tuberc Lung Dis; 2007 Mar; 11(3):319-24. PubMed ID: 17352099
[TBL] [Abstract][Full Text] [Related]
2. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
3. Assessment of trends of ofloxacin resistance in Mycobacterium tuberculosis.
Verma JS; Nair D; Rawat D; Manzoor N
Indian J Med Microbiol; 2011; 29(3):280-2. PubMed ID: 21860110
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.
Ramachandran R; Nalini S; Chandrasekar V; Dave PV; Sanghvi AS; Wares F; Paramasivan CN; Narayanan PR; Sahu S; Parmar M; Chadha S; Dewan P; Chauhan LS
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1154-60. PubMed ID: 19723407
[TBL] [Abstract][Full Text] [Related]
5. HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients--a trend.
Rajasekaran S; Chandrasekar C; Mahilmaran A; Kanakaraj K; Karthikeyan DS; Suriakumar J
J Indian Med Assoc; 2009 May; 107(5):281-2, 284-6. PubMed ID: 19886382
[TBL] [Abstract][Full Text] [Related]
6. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Mamatha HG; Shanthi V
J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289
[TBL] [Abstract][Full Text] [Related]
7. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
[TBL] [Abstract][Full Text] [Related]
8. Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates.
Jain A; Dixit P; Prasad R
Tuberculosis (Edinb); 2012 Sep; 92(5):404-6. PubMed ID: 22789499
[TBL] [Abstract][Full Text] [Related]
9. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility.
Kam KM; Yip CW; Cheung TL; Tang HS; Leung OC; Chan MY
Microb Drug Resist; 2006; 12(1):7-11. PubMed ID: 16584301
[TBL] [Abstract][Full Text] [Related]
10. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey.
Umubyeyi AN; Rigouts L; Shamputa IC; Fissette K; Elkrim Y; de Rijk PW; Struelens MJ; Portaels F
J Antimicrob Chemother; 2007 May; 59(5):1031-3. PubMed ID: 17329272
[TBL] [Abstract][Full Text] [Related]
11. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan.
Lai CC; Tan CK; Huang YT; Chou CH; Hung CC; Yang PC; Luh KT; Hsueh PR
Clin Infect Dis; 2008 Oct; 47(7):e57-63. PubMed ID: 18715157
[TBL] [Abstract][Full Text] [Related]
12. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia.
Jugheli L; Rigouts L; Shamputa IC; Bram de Rijk W; Portaels F
Int J Tuberc Lung Dis; 2008 May; 12(5):561-6. PubMed ID: 18419893
[TBL] [Abstract][Full Text] [Related]
13. Thin-layer agar for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium tuberculosis isolates.
Martin A; Paasch F; Von Groll A; Fissette K; Almeida P; Varaine F; Portaels F; Palomino JC
Int J Tuberc Lung Dis; 2009 Oct; 13(10):1301-4. PubMed ID: 19793437
[TBL] [Abstract][Full Text] [Related]
14. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.
Casal M; Ruiz P; Herreras A
Int J Tuberc Lung Dis; 2000 Jun; 4(6):588-91. PubMed ID: 10864193
[TBL] [Abstract][Full Text] [Related]
15. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
Umubyeyi A; Rigouts L; Shamputa IC; Dediste A; Struelens M; Portaels F
Int J Infect Dis; 2008 Mar; 12(2):152-6. PubMed ID: 17950021
[TBL] [Abstract][Full Text] [Related]
16. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study].
Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566
[TBL] [Abstract][Full Text] [Related]
17. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis.
Törün T; Tahaoğlu K; Ozmen I; Sevim T; Ataç G; Kir A; Güngör G; Bölükbaşi Y; Maden E
Int J Tuberc Lung Dis; 2007 Sep; 11(9):979-85. PubMed ID: 17705975
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistant tuberculosis in Castilla-León, Spain, 1996-2000.
Alberte-Castiñeiras A; Brezmes-Valdivieso MF; Campos-Bueno A; Montes-Martinez I; López-Medrano R; Avellaneda C; Pérez-Pascual P; Della-Latta P
Int J Tuberc Lung Dis; 2006 May; 10(5):554-8. PubMed ID: 16704039
[TBL] [Abstract][Full Text] [Related]
20. [A preliminary study on the definition of resistant breakpoints of ofloxacin and levofloxacin for Mycobacterium tuberculosis].
Huang XR; Gao WW; Zhang XX; Wang SM; Pan YX; Ma Y
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Feb; 27(2):84-8. PubMed ID: 14990180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
